- Home
- CCD vs DAWN Comparison
CCD vs DAWN Comparison
Compare CCD & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCD | DAWN |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 581.7M | 624.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CCD | DAWN |
|---|---|---|
| Price | $21.42 | $8.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $26.56 |
| AVG Volume (30 Days) | 96.1K | ★ 2.8M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 10.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $133,672,000.00 |
| Revenue This Year | N/A | $15.51 |
| Revenue Next Year | N/A | $49.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 31.11 |
| 52 Week Low | $16.93 | $5.64 |
| 52 Week High | $24.68 | $14.46 |
Technical Indicators
Market Signals| Indicator | CCD | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 55.53 | 48.23 |
| Support Level | $19.99 | $8.16 |
| Resistance Level | $21.40 | $9.72 |
| Average True Range (ATR) | 0.40 | 0.53 |
| MACD | 0.08 | -0.13 |
| Stochastic Oscillator | 95.02 | 17.45 |
Price Performance
Historical ComparisonAbout CCD Calamos Dynamic Convertible & Income Fund
Calamos Dynamic Convertible and Income Fund operates as a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. It predominantly invests in a portfolio of convertible securities, investment grade and below investment grade bonds, loans, equity-linked notes, and floating rate securities.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.